Clinical trial NCT05069415: Monofocal IOL Visual Outcomes When Targeting Mini Monovision
Official title: Visual Performance and Patient Satisfaction With A New Monofocal Intraocular Lens
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract
Presbyopia
Lead sponsor: Carolina Eyecare Physicians, LLC
Sponsor class: OTHER
First posted: 2021-10-06
Enrollment: 75
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study is a 3-month, prospective, up to 2 center, bilateral, randomized subject masked clinical evaluation of a monofocal intraocular lens (IOL) when both eyes are targeted for emmetropia and when the non-dominant eye is targeted for mini monovision (-0.75 D) in patients with or without astigmatism undergoing routine cataract surgery.


Eligibility criteria: Inclusion Criteria:

* Subject is undergoing bilateral cataract extraction with intraocular lens implantation.
* Willing and able to provide written informed consent for participation in the study
* Willing and able to comply with scheduled visits and other study procedures.
* Scheduled to undergo standard cataract surgery in both eyes within 6 - 30 days between surgeries.
* Subjects who require an IOL power in the range of +5.0 D to +34.0 D only.
* Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.

Exclusion Criteria:

* Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.
* Uncontrolled diabetes.
* Use of any systemic or topical drug known to interfere with visual performance.
* Contact lens use during the active treatment portion of the trial.
* Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
* Clinically significant corneal dystrophy.
* Irregular astigmatism.
* History of chronic intraocular inflammation.
* History of retinal detachment.
* Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
* Previous intraocular surgery.
* Previous refractive surgery.
* Previous keratoplasty
* Severe dry eye
* Pupil abnormalities
* Subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy, i.e. LASIK)
* Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).
* Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
* Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.

Primary outcomes:
measure: Binocular Distance-corrected Intermediate (66 cm) Visual Acuity at 3 Months.
timeFrame: 3 months
Secondary outcomes:
measure: Binocular Low Contrast Distance Visual Acuity at 3 Months
timeFrame: 3 months
measure: Distance-corrected Near Visual Acuity at Best Distance at 3 Months
timeFrame: 3 months
Other outcomes:
Locations:
city: Sarasota
country: United States
facility: Center for Sight
state: Florida
city: Mount Pleasant
country: United States
facility: Carolina Eyecare Physicians, LLC
state: South Carolina
Study officials:
affiliation: Carolina Eyecare Physicians
name: Kerry D Solomon
role: PRINCIPAL_INVESTIGATOR
References: